Company intelligence / Profile preview

Campa

Cambridge, Massachusetts, USA

Ownership: Private
Employees: ~100
Development stage: Other

Overview

Camp4 Therapeutics is a clinical-stage biotechnology company pioneering a new approach to programmable RNA medicines. The company's proprietary Regulatory RNA Activating Platform (RAP) identifies and targets regulatory RNAs (regRNAs) that control the expression of specific protein-coding genes. By using antisense oligonucleotides (ASOs) to modulate these regRNAs, Camp4 can precisely upregulate protein production to treat diseases caused by haploinsufficiency or protein deficiency. Their pipeline focuses on genetic diseases of the liver and central nervous system, including Dravet syndrome and urea cycle disorders.

Therapeutic areas: NeurologyMetabolic Disorders
Modalities: RNA therapyAntisense oligonucleotideSmall molecule
Industry: Biotech

Partnerships

Alnylam PharmaceuticalsBiogen

Beyond the preview

Go deeper on Campa.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Campa.

Explore the full profile